RA Capital Healthcare Fund LP's Form 4 filing
Climb Bio, Inc.CLYM · filed Jul 1, 2024
- Accession no.
- 0001415889-24-018708
- Filed
- Jul 1, 2024, 9:29 PM ET
- Trade date
- Jun 27, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market purchases total $50.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund, L.P.CIK 0001780117 | Director |
| RA Capital Nexus Fund II, L.P.CIK 0001825376 | Director |
| RA Capital Nexus Fund III, L.P.CIK 0001883840 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2024 | Common Stock | AGrant or awardAcquired | +973,000 | –F1 | – | 11,572,586 | Indirect | |
| Jun 27, 2024 | Common Stock | AGrant or awardAcquired | +2,479,872 | –F1 | – | 2,479,872 | Indirect | |
| Jun 27, 2024 | Common Stock | AGrant or awardAcquired | +1,807,000 | –F1 | – | 1,807,000 | Indirect | |
| Jun 27, 2024 | Common Stock | PPurchaseAcquired | +11,949,171 | $3.84 | +$45,884,816.64 | 23,521,757 | Indirect | |
| Jun 27, 2024 | Common Stock | PPurchaseAcquired | +1,059,375 | $3.84 | +$4,068,000 | 2,866,375 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Received in exchange for equity of Tenet Medicines, Inc. ("Tenet") pursuant to an Agreement and Plan of Merger and Reorganization, dated April 10, 2024, by and among the Issuer, Tango Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Tango Merger Sub") and Tenet (the "Acquisition Agreement"). Under the terms of the Acquisition Agreement, on June 27, 2024, Tenet was acquired by the Issuer through the merged of Tango Merger Sub with and into Tenet (the "Acquisition"), with Tenet surviving the Acquisition as a wholly-owned subsidiary of the Issuer.
Referenced by the price of 3 transactions in Table I.
Remarks
Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on the Issuer's board of directors.